These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6897455)

  • 21. [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
    Palmieri G; Perego M; Nazzari M; Casalini F
    Clin Ter; 1982 Jun; 101(6):603-14. PubMed ID: 7128029
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled trials of fish oil supplements on plasma lipid concentrations.
    Sanders TA; Mistry M
    Br J Clin Pract Suppl; 1984; 31():78-84. PubMed ID: 6091724
    [No Abstract]   [Full Text] [Related]  

  • 25. Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV.
    Povoa H; Sá LD; Lessa VM
    Biomed Biochim Acta; 1984; 43(10):1201-3. PubMed ID: 6549257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Insulinemia in hypertriglyceridemia caused by long-term carbohydrate-rich diet].
    Młyński J
    Kardiol Pol; 1981; 24(9):611-7. PubMed ID: 7029112
    [No Abstract]   [Full Text] [Related]  

  • 27. [Combined familial hyperlipidemia: genetics, lipidic composition and differences with familial hypertriglyceridemia type IV].
    Delgado M; Torres MA; Bellod P; Rubio MJ; Nuño J; de Oya M
    Med Clin (Barc); 1985 Dec; 85(19):792-7. PubMed ID: 4094500
    [No Abstract]   [Full Text] [Related]  

  • 28. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ; del Rio A; González-Viejo N; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypertriglyceridemia--independent risk factor or risk marker?
    Hanefeld M; Lüthke K
    Przegl Lek; 1989; 46(7):588-94. PubMed ID: 2587786
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P; Bittolo-Bon G; Alessandrini P
    Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 33. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 34. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of dyslipidemias with DEAE-dextran].
    Barone A; Gaggi S; Pulido ME; Pupita F
    Clin Ter; 1985 Dec; 115(6):469-75. PubMed ID: 2420508
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of long-term hypolipemic treatment with bezafibrate on the lithogenesis of bile in persons with endogenous hypertriglyceridemia].
    Hrabák P; Zák A; Zeman M; Skorepa J; Hrubant K
    Cas Lek Cesk; 1986 May; 125(21):651-4. PubMed ID: 3708672
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.